The University of Oxford receives its first batch of AZD1222, a coronavirus vaccine candidate.
Academics at the Jenner Institute at the University of Oxford, UK, have received 4000
doses of AZD1222 (formerly known as ChAdOx1 nCoV-19) for use in a Phase 2/3
trial from Italian contract manufacturer Advent, part of the IRBM Group.
Credit: Advent, IRBM
Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.
February 3, 2025
4 min read
With new cases of avian influenza appearing, what does this mean for global health and what are drug developers doing about it?
December 1, 2014
0 min read
Can phage endolysins revolutionize the way bacterial infections are treated – and prevent drug resistance?
April 2, 2025
2 min read
How fluid flow through the body can affect the ways in which antibiotics work.
April 7, 2025
4 min read
Celon Pharma CEO hopes their new compound could be a potential breakthrough for Parkinson’s patients.